

Catalog# BP- 50503

Infliximab Biosimilar (TNF alpha Monoclonal Antibody)

Infliximab, a chimeric anti-TNF- α monoclonal antibody, is used to treat psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Infliximab interferes TNF- α from binding to its receptor in the cell.

Mainly produced by activated macrophages (M1), Tumor necrosis factor (TNF, cachexin, cachectin, tumor necrosis factor alpha, TNF α) plays important roles in the regulation of autoimmune reaction.

Product Details	
CAS No.	N/A
Species Reactivity	Human
Source	Infliximab biosimilar CHO stable cell line
Isotype	Human IgG1 kappa
Class	Monoclonal
Type	Antibody
Clone	Infliximab Biosimilar
Conjugate	Unconjugated
Immunogen	Human TNF alpha
Purity	>95%
Molecular Weight	145.886 kDa
Protein Concentration	1 mg/ml
Formulation	0. 0.2 μ M filtered solution, pH 7.2
Storage conditions	4°C for short time, -20°C or -80°C for long time.